02496 YZYBIO-B
- 6.170
- -0.030-0.48%
YZYBIO-B News
YZYBIO-B: Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 August 2024
YZYBIO-B: LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS
YZYBIO-B: PROPOSED AMENDMENTS TO THE ARTICLES OF ASSOCIATION AND APPOINTMENT OF A MEMBER OF NOMINATION COMMITTEE AND COMPLIANCE WITH THE LISTING RULES
YZYBIO-B: INSIDE INFORMATION ANNOUNCEMENT
YZYBIO-B: Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 July 2024
YZYBIO-B: LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS
YZYBIO-B: RESIGNATION OF INDEPENDENT NON-EXECUTIVE DIRECTOR
YZYBIO-B: Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 June 2024
YZYBIO-B: Articles of Association
YZYBIO-B: Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 May 2024
YZYBIO-B: FORM OF PROXY FOR THE ANNUAL GENERAL MEETING OF 2023
YZYBIO-B: PROPOSED AMENDMENTS TO THE ARTICLES OF ASSOCIATION
YZYBIO-B: VOLUNTARY ANNOUNCEMENT - PHASE II STUDY DATA OF M701 FOR THE TREATMENT OFMALIGNANT ASCITES PRESENTED AT THE 2024 ASCO MEETING
YZYBIO-B: Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 April 2024
YZYBIO-B: LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS
YZYBIO-B: RESIGNATION OF NON-EXECUTIVE DIRECTOR
YZYBIO-B: 2023 ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT
YZYBIO-B: Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 March 2024
YZYBIO-B: VOLUNTARY ANNOUNCEMENT -THE FIRST PATIENT ENROLLED IN PHASE III CLINICAL TRIAL OFM701, A BISPECIFIC ANTIBODY FOR TREATMENT OF MALIGNANTASCITES
YZYBIO-B: VOLUNTARY ANNOUNCEMENT - THE FIRST PATIENT ENROLLED IN PHASE II CLINICALTRIAL OF M701, A BISPECIFIC ANTIBODY FOR TREATMENT OFMALIGNANT PLEURAL EFFUSION
Analysis
Price Target
No Data
No Data